- $34.87m
- -$145.60m
- $31.37m
Brief: EyePoint Pharmaceuticals Appoints Fred Hassan To Board Of Directors
U.S. RESEARCH ROUNDUP- Apollo, Blackstone, Hershey
EyePoint Pharmaceuticals Inc reports results for the quarter ended in January - Earnings Summary
Brief: EyePoint Pharmaceuticals Inc Files For Mixed Shelf Of Up To $400 Million – SEC Filing
EyePoint Pharmaceuticals Inc expected to post a loss of 57 cents a share - Earnings Preview
EyePoint Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
U.S. STOCKS ON THE MOVE-GoDaddy, Walt Disney, Aerovironment
U.S. STOCKS ON THE MOVE-NAPCO Security Technologies, Outset Medical, US energy sector
U.S. STOCKS ON THE MOVE-U.S. Steel, Freshpet, oil stocks
EyePoint Pharma down as eye drug misses main goal in mid-stage trial
EyePoint Pharmaceuticals Inc expected to post a loss of 41 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Teladoc Health, Hamilton Insurance, SciSparc
U.S. STOCKS ON THE MOVE-SciSparc, gold miners, Teladoc
EyePoint Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
U.S. STOCKS ON THE MOVE-Kroger, Chemours, Vital Farms
EyePoint climbs on Q4 revenue beat
Brief: EyePoint Pharmaceuticals Q4 basic EPS USD -0.33
EyePoint Pharmaceuticals Inc expected to post a loss of 49 cents a share - Earnings Preview
Brief: Eyepoint Says Previously Reported Positive Phase 2 Davio 2 Topline Results Showing All Primary & Secondary Endpoints Were Met